MAIO, MICHELE
MAIO, MICHELE
Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze
5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?
2003-01-01 Sigalotti, L; Altomonte, M; Colizzi, F; Degan, M; Rupolo, M; Zagonel, V; Pinto, A; Gattei, V; Maio, M
5-AZA-2'-deoxycytidine in cancer immunotherapy: a mouse to man story
2007-01-01 Coral, S; Sigalotti, L; Covre, A; Nicolay, Hj; Natali, Pg; Maio, M
5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications
2002-01-01 Coral, S; Sigalotti, L; Altomonte, M; Engelsberg, A; Colizzi, F; Cattarossi, I; Maraskovsky, E; Jager, E; Seliger, B; Maio, M
5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: Extended follow-up of the coBRIM study
2021-01-01 Ascierto, P. A.; Dreno, B.; Larkin, J.; Ribas, A.; Liszkay, G.; Maio, M.; Mandala, M.; Demidov, L.; Stroyakovskiy, D.; Thomas, L.; de la Cruz-Merino, L.; Atkinson, V.; Dutriaux, C.; Garbe, C.; Hsu, J.; Jones, S.; Li, H.; Mckenna, E.; Voulgari, A.; Mcarthur, G. A.
A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis
2024-01-01 Valente, M.; Colucci, M.; Vegni, V.; Croce, V.; Bellan, C.; Rossi, G.; Gibilisco, G.; Frongia, F.; Guazzo, R.; Ghiribelli, C.; Bargagli, E.; Savelli, V.; Ravara, M.; Sani, T.; Simonetti, E.; Maio, M.; Calabrò, L.; Di Giacomo, A. M.
A novel microRNA signature for the detection of melanoma by liquid biopsy
2022-01-01 Sabato, Claudia; Noviello, Teresa Maria Rosaria; Covre, Alessia; Coral, Sandra; Caruso, Francesca Pia; Besharat, Zein Mersini; Splendiani, Elena; Masuelli, Laura; Battistelli, Cecilia; Vacca, Alessandra; Catanzaro, Giuseppina; Po, Agnese; Anichini, Andrea; Maio, Michele; Ceccarelli, Michele; Di Giacomo, Anna Maria; Ferretti, Elisabetta
A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: the NIBIT-M4 Study.
2016-01-01 DI GIACOMO, ANNA MARIA; Covre, Alessia; Taverna, Pietro; Coral, Sandra; Amato, Giovanni; Keer, Harold N.; Lowder, James N.; Giannarelli, Diana; Azab, Mohammad; Maio, Michele
A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial
2011-01-01 DI GIACOMO, ANNA MARIA; Ascierto, Pa; Pittiglio, E; Queirolo, P; Pilla, L; Ridolfi, R; Santinami, M; Testori, A; Parmiani, G; Maio, M
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients
2006-01-01 Pilla, L; Patuzzo, R; Rivoltini, L; Maio, M; Pennacchioli, E; Lamaj, E; Maurichi, A; Massarut, S; Marchianò, A; Santantonio, C; Tosi, D; Arienti, F; Cova, A; Sovena, G; Piris, A; Nonaka, D; Bersani, I; Di Florio, A; Luigi, M; Srivastava, Pk; Hoos, A; Santinami, M; Parmiani, G
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma
2014-01-01 Hamid, O.; Ilaria, Jr. R.; Garbe, C.; Wolter, P.; Maio, M.; Hutson, T. E.; Arance, A.; Lorigan, P.; Lee, J.; Hauschild, A.; Mohr, P.; Hahka-Kemppinen, M.; Kaiser, C.; Turner, P. K.; Conti, I.; Grob, J. -J.
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
2008-01-01 Butterfield, Lh; Disis, Ml; Fox, Ba; Lee, Pp; Khleif, Sn; Thurin, M; Trinchieri, G; Wang, E; Wigginton, J; Chaussabel, D; Coukos, G; Dhodapkar, M; Håkansson, L; Janetzki, S; Kleen, To; Kirkwood, Jm; Maccalli, C; Maecker, H; Maio, M; Malyguine, A; Masucci, G; Palucka, Ak; Potter, Dm; Ribas, A; Rivoltini, L; Schendel, D; Seliger, B; Selvan, S; Slingluff CL, Jr; Stroncek, Df; Streicher, H; Wu, X; Zeskind, B; Zhao, Y; Zocca, Mb; Zwierzina, H; Marincola, Fm.
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation
2021-01-01 Maio, M.; Lahn, M.; Di Giacomo, A. M.; Covre, A.; Calabro, L.; Ibrahim, R.; Fox, B.; Abrignani, S.; Paola, A.; Anichini, A.; Ardizzoni, A.; Gregorio, A.; Azab, M.; Ballas, M.; Barberis, M.; Bayless, N. L.; Bell, B.; Bifarini, A.; Blank, C.; Brodin, P.; Camerini, R.; Ennio, C.; Ceccarelli, M.; Francesca, C.; Connolly, J.; Sandra, C.; Cornelissen, R.; Eggermont, A.; Eid, J.; Fajgenbaum, D.; Ferretti, E.; Ferrone, S.; Finotello, F.; Flaherty, K.; Ester, F.; Elisabetta, F.; Fridman, C. S.; Fridman, W. H.; Garcia, P.; Gherardini, P. F.; Goonewardene, A.; Hacking, G.; Heller, K.; Hulett, T. W.; Michael, I.; Jacobson, D.; Janek, M.; Joho, S.; Keer, H.; Kleif, S.; Kotecha, N.; Kotter, M.; Krogan, N.; Lanzavecchia, A.; Locatelli, F.; Lollini, P. -L.; Mantovani, A.; Melacarne, A.; Melillo, G.; Menden, M.; Minerva, D.; Moretta, L.; Namouni, F.; Natali, P. G.; Necchi, A.; Nistico, P.; Cosimo, P.; Giuseppe, P.; Pardoll, D.; Paz-Ares, L.; Plessala, K.; Peters, S.; Prins, R. M.; Provendier, O.; Rappuoli, R.; Rescigno, M.; Ruettinger, D.; Seliger, B.; Sette, A.; Luca, S.; Spasic, M.; Tortora, G.; Trajanoski, Z.; Tunici, P.; Vitale, C.; Wigginton, J.; Yadav, M.; Yu, H.
Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
2023-01-01 Yadavilli, Sapna; Waight, Jeremy D; Brett, Sara; Bi, Meixia; Zhang, Tianqian; Liu, Yao-Bin; Ellis, Catherine; Turner, David C; Hahn, Ashleigh; Shi, Hong; Seestaller-Wehr, Laura; Jing, Junping; Xie, Qing; Shaik, Jafar Sadik; Ji, Xiao; Gagnon, Robert; Fieles, William; Hook, Laura; Grant, Steven; Hopley, Stephanie; Deyoung, M Phillip; Blackwell, Christina; Chisamore, Michael; Biddlecombe, Robert; Figueroa, David J; Hopson, Christopher B; Srinivasan, Roopa; Smothers, James; Maio, Michele; Rischin, Danny; Olive, Daniel; Paul, Elaine; Mayes, Patrick A; Hoos, Axel; Ballas, Marc
Active immunization of melanoma patients with IL-2- or IL-4-transduced allogeneic melanoma cells
1997-01-01 Arienti, F; Belli, F; Mazzocchi, A; Gallino, F; Napolitano, F; Melani, C; Colombo, Mp; Rivoltini, L; Maio, M; Parmiani, G
Active immunization of melanoma patients with IL-2-transfected allogeneic melanoma cells. A phase I-II study
1995-01-01 Arienti, F; Belli, F; Sulesuso, J; Maio, M; Mascheroni, L; Melani, C
Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability
1997-01-01 Belli, F; Arienti, F; Sulesuso, J; Clemente, C; Mascheroni, L; Cattelan, A; Sanantonio, C; Gallino, Gf; Melani, C; Rao, S; Colombo, Mp; Maio, M; Cascinelli, N; Parmiani, G
Activity of ipilimumab at 10mg/kg in patients with advanced melanoma is independent of baseline prognostic factors
2009-01-01 Schadendorf, D; Wolchok, J; Neyns, B; Lebbe, C; Harmankaya, K; Verschraegen, C; Chin, K; de Pril, V; Hoos, A; Maio, M
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy
2019-01-01 Maio, M.; Coukos, G.; Ferrone, S.; Fox, B. A.; Fridman, W. H.; Garcia, P. L.; Lahn, M.; Provendier, O.; Russo, V.; Ruttinger, D.; Shalabi, A.; Trajanoski, Z.; Viallet, J.; Wolchok, J. D.; Ibrahim, R.
Adjuncts in diagnosis, prognosis, and clinical monitoring of breast, gynecologic, and hematolymphopoietic malignancies: Third Joint International Workshop, Lacco Ameno d'Ischia, Italy, October 2001
2002-01-01 Giordano, Gg; Sigalotti, L; Maio, M
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial
2015-01-01 Eggermont, A. M. M.; Chiarion-Sileni, V.; Grob, J. -J.; Dummer, R.; Wolchok, J. D.; Schmidt, H.; Hamid, O.; Robert, C.; Ascierto, P. A.; Richards, J. M.; Lebbe, C.; Ferraresi, V.; Smylie, M.; Weber, J. S.; Maio, M.; Konto, C.; Hoos, A.; de Pril, V.; Gurunath, R. K.; de Schaetzen, G.; Suciu, S.; Testori, A.
| Titolo | Data di pubblicazione | Autore(i) | File | Abstract |
|---|---|---|---|---|
| 5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? | 1-gen-2003 | Sigalotti, L; Altomonte, M; Colizzi, F; Degan, M; Rupolo, M; Zagonel, V; Pinto, A; Gattei, V; Maio, M | - | |
| 5-AZA-2'-deoxycytidine in cancer immunotherapy: a mouse to man story | 1-gen-2007 | Coral, S; Sigalotti, L; Covre, A; Nicolay, Hj; Natali, Pg; Maio, M | - | |
| 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications | 1-gen-2002 | Coral, S; Sigalotti, L; Altomonte, M; Engelsberg, A; Colizzi, F; Cattarossi, I; Maraskovsky, E; Jager, E; Seliger, B; Maio, M | - | |
| 5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: Extended follow-up of the coBRIM study | 1-gen-2021 | Ascierto, P. A.; Dreno, B.; Larkin, J.; Ribas, A.; Liszkay, G.; Maio, M.; Mandala, M.; Demidov, L.; Stroyakovskiy, D.; Thomas, L.; de la Cruz-Merino, L.; Atkinson, V.; Dutriaux, C.; Garbe, C.; Hsu, J.; Jones, S.; Li, H.; Mckenna, E.; Voulgari, A.; Mcarthur, G. A. | - | |
| A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis | 1-gen-2024 | Valente, M.; Colucci, M.; Vegni, V.; Croce, V.; Bellan, C.; Rossi, G.; Gibilisco, G.; Frongia, F.; Guazzo, R.; Ghiribelli, C.; Bargagli, E.; Savelli, V.; Ravara, M.; Sani, T.; Simonetti, E.; Maio, M.; Calabrò, L.; Di Giacomo, A. M. | - | |
| A novel microRNA signature for the detection of melanoma by liquid biopsy | 1-gen-2022 | Sabato, Claudia; Noviello, Teresa Maria Rosaria; Covre, Alessia; Coral, Sandra; Caruso, Francesca Pia; Besharat, Zein Mersini; Splendiani, Elena; Masuelli, Laura; Battistelli, Cecilia; Vacca, Alessandra; Catanzaro, Giuseppina; Po, Agnese; Anichini, Andrea; Maio, Michele; Ceccarelli, Michele; Di Giacomo, Anna Maria; Ferretti, Elisabetta | - | |
| A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: the NIBIT-M4 Study. | 1-gen-2016 | DI GIACOMO, ANNA MARIA; Covre, Alessia; Taverna, Pietro; Coral, Sandra; Amato, Giovanni; Keer, Harold N.; Lowder, James N.; Giannarelli, Diana; Azab, Mohammad; Maio, Michele | - | |
| A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial | 1-gen-2011 | DI GIACOMO, ANNA MARIA; Ascierto, Pa; Pittiglio, E; Queirolo, P; Pilla, L; Ridolfi, R; Santinami, M; Testori, A; Parmiani, G; Maio, M | - | |
| A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients | 1-gen-2006 | Pilla, L; Patuzzo, R; Rivoltini, L; Maio, M; Pennacchioli, E; Lamaj, E; Maurichi, A; Massarut, S; Marchianò, A; Santantonio, C; Tosi, D; Arienti, F; Cova, A; Sovena, G; Piris, A; Nonaka, D; Bersani, I; Di Florio, A; Luigi, M; Srivastava, Pk; Hoos, A; Santinami, M; Parmiani, G | - | |
| A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma | 1-gen-2014 | Hamid, O.; Ilaria, Jr. R.; Garbe, C.; Wolter, P.; Maio, M.; Hutson, T. E.; Arance, A.; Lorigan, P.; Lee, J.; Hauschild, A.; Mohr, P.; Hahka-Kemppinen, M.; Kaiser, C.; Turner, P. K.; Conti, I.; Grob, J. -J. | - | |
| A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers" | 1-gen-2008 | Butterfield, Lh; Disis, Ml; Fox, Ba; Lee, Pp; Khleif, Sn; Thurin, M; Trinchieri, G; Wang, E; Wigginton, J; Chaussabel, D; Coukos, G; Dhodapkar, M; Håkansson, L; Janetzki, S; Kleen, To; Kirkwood, Jm; Maccalli, C; Maecker, H; Maio, M; Malyguine, A; Masucci, G; Palucka, Ak; Potter, Dm; Ribas, A; Rivoltini, L; Schendel, D; Seliger, B; Selvan, S; Slingluff CL, Jr; Stroncek, Df; Streicher, H; Wu, X; Zeskind, B; Zhao, Y; Zocca, Mb; Zwierzina, H; Marincola, Fm. | - | |
| A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation | 1-gen-2021 | Maio, M.; Lahn, M.; Di Giacomo, A. M.; Covre, A.; Calabro, L.; Ibrahim, R.; Fox, B.; Abrignani, S.; Paola, A.; Anichini, A.; Ardizzoni, A.; Gregorio, A.; Azab, M.; Ballas, M.; Barberis, M.; Bayless, N. L.; Bell, B.; Bifarini, A.; Blank, C.; Brodin, P.; Camerini, R.; Ennio, C.; Ceccarelli, M.; Francesca, C.; Connolly, J.; Sandra, C.; Cornelissen, R.; Eggermont, A.; Eid, J.; Fajgenbaum, D.; Ferretti, E.; Ferrone, S.; Finotello, F.; Flaherty, K.; Ester, F.; Elisabetta, F.; Fridman, C. S.; Fridman, W. H.; Garcia, P.; Gherardini, P. F.; Goonewardene, A.; Hacking, G.; Heller, K.; Hulett, T. W.; Michael, I.; Jacobson, D.; Janek, M.; Joho, S.; Keer, H.; Kleif, S.; Kotecha, N.; Kotter, M.; Krogan, N.; Lanzavecchia, A.; Locatelli, F.; Lollini, P. -L.; Mantovani, A.; Melacarne, A.; Melillo, G.; Menden, M.; Minerva, D.; Moretta, L.; Namouni, F.; Natali, P. G.; Necchi, A.; Nistico, P.; Cosimo, P.; Giuseppe, P.; Pardoll, D.; Paz-Ares, L.; Plessala, K.; Peters, S.; Prins, R. M.; Provendier, O.; Rappuoli, R.; Rescigno, M.; Ruettinger, D.; Seliger, B.; Sette, A.; Luca, S.; Spasic, M.; Tortora, G.; Trajanoski, Z.; Tunici, P.; Vitale, C.; Wigginton, J.; Yadav, M.; Yu, H. | - | |
| Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade | 1-gen-2023 | Yadavilli, Sapna; Waight, Jeremy D; Brett, Sara; Bi, Meixia; Zhang, Tianqian; Liu, Yao-Bin; Ellis, Catherine; Turner, David C; Hahn, Ashleigh; Shi, Hong; Seestaller-Wehr, Laura; Jing, Junping; Xie, Qing; Shaik, Jafar Sadik; Ji, Xiao; Gagnon, Robert; Fieles, William; Hook, Laura; Grant, Steven; Hopley, Stephanie; Deyoung, M Phillip; Blackwell, Christina; Chisamore, Michael; Biddlecombe, Robert; Figueroa, David J; Hopson, Christopher B; Srinivasan, Roopa; Smothers, James; Maio, Michele; Rischin, Danny; Olive, Daniel; Paul, Elaine; Mayes, Patrick A; Hoos, Axel; Ballas, Marc | - | |
| Active immunization of melanoma patients with IL-2- or IL-4-transduced allogeneic melanoma cells | 1-gen-1997 | Arienti, F; Belli, F; Mazzocchi, A; Gallino, F; Napolitano, F; Melani, C; Colombo, Mp; Rivoltini, L; Maio, M; Parmiani, G | - | |
| Active immunization of melanoma patients with IL-2-transfected allogeneic melanoma cells. A phase I-II study | 1-gen-1995 | Arienti, F; Belli, F; Sulesuso, J; Maio, M; Mascheroni, L; Melani, C | - | |
| Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability | 1-gen-1997 | Belli, F; Arienti, F; Sulesuso, J; Clemente, C; Mascheroni, L; Cattelan, A; Sanantonio, C; Gallino, Gf; Melani, C; Rao, S; Colombo, Mp; Maio, M; Cascinelli, N; Parmiani, G | - | |
| Activity of ipilimumab at 10mg/kg in patients with advanced melanoma is independent of baseline prognostic factors | 1-gen-2009 | Schadendorf, D; Wolchok, J; Neyns, B; Lebbe, C; Harmankaya, K; Verschraegen, C; Chin, K; de Pril, V; Hoos, A; Maio, M | - | |
| Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy | 1-gen-2019 | Maio, M.; Coukos, G.; Ferrone, S.; Fox, B. A.; Fridman, W. H.; Garcia, P. L.; Lahn, M.; Provendier, O.; Russo, V.; Ruttinger, D.; Shalabi, A.; Trajanoski, Z.; Viallet, J.; Wolchok, J. D.; Ibrahim, R. | - | |
| Adjuncts in diagnosis, prognosis, and clinical monitoring of breast, gynecologic, and hematolymphopoietic malignancies: Third Joint International Workshop, Lacco Ameno d'Ischia, Italy, October 2001 | 1-gen-2002 | Giordano, Gg; Sigalotti, L; Maio, M | - | |
| Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial | 1-gen-2015 | Eggermont, A. M. M.; Chiarion-Sileni, V.; Grob, J. -J.; Dummer, R.; Wolchok, J. D.; Schmidt, H.; Hamid, O.; Robert, C.; Ascierto, P. A.; Richards, J. M.; Lebbe, C.; Ferraresi, V.; Smylie, M.; Weber, J. S.; Maio, M.; Konto, C.; Hoos, A.; de Pril, V.; Gurunath, R. K.; de Schaetzen, G.; Suciu, S.; Testori, A. | - |